Southwest Brain Bank Launches PFS Brain and Spinal Cord Donation Program
SOMERSET, N.J., July 15, 2015 – The Southwest Brain Bank (SWBB) in the Department of Psychiatry at the University of Texas Health Science Center in San Antonio has received its first donation of the brain and spinal cord of a post-finasteride syndrome (PFS) patient and formed a program to collect and study post-mortem human brain […]
U.S. National Institutes of Health Adds PFS to Genetic and Rare Diseases Info Center
May 19, 2015 Dear Public Health Official: The U.S. National Institutes of Health recently added post-finasteride syndrome (PFS) to its Genetic and Rare Diseases Information Center, noting that: “Studies are underway to understand the safety profile of 5-alpha reductase inhibitor drugs with respect to adverse events…and their permanency.” This federal listing of PFS comes in […]
Number of Nations Logging onto PFS Foundation Website Rises 22% in 2014
SOMERSET, N.J., Jan. 6, 2015 – The number of nations that logged onto the Post-Finasteride Syndrome Foundation website jumped 22 percent in 2014, according to Google Analytics. In all, users in 157 countries—or 81 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed information on the condition […]
Clinical Study of Post-Finasteride Syndrome Launched at University of Milano-Bicocca and University of Milano
SOMERSET, N.J., Dec. 9, 2014 – The Post-Finasteride Syndrome Foundation today announced the funding of a third clinical study on post-finasteride syndrome (PFS), this one a collaboration between the University of Milano-Bicocca and the University of Milano, both in Italy. Titled “Rare, but Serious and Persistent, Side Effects of 5α Reductase Inhibitors (5ARI): Why Do […]
2014 PFS Foundation Annual Address
Aug. 4, 2014 Dear Friends: I’m pleased to report that 2014 is shaping up to be a turning point on the road to widespread awareness of post-finasteride syndrome. Couple that with the steady progress of our clinical studies and I become ever more hopeful that the coming year will bring not only worldwide acceptance of […]
Number of Nations Logging onto PFS Foundation Website Rises Another 26% in First Half of 2014
SOMERSET, N.J., July 8, 2014 – The number of nations that logged onto the Post-Finasteride Syndrome Foundation website rose 26 percent during the first half of 2014, according to Google Analytics. In all, users in 147 countries—or 75 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed […]
Doctors Recruiting PFS Patients for Research Studies
SOMERSET, N.J., June 16, 2014 – Post-finasteride syndrome research initiatives at two major U.S. medical institutions, Brigham and Women’s Hospital (a Harvard Medical School Teaching Affiliate) in Boston, Mass., and Baylor College of Medicine in Houston, Texas, are currently recruiting patients for their respective studies on the condition. If you are interested in participating, or […]
Daniel M. Stewart: 1976-2014
April 25, 2014 Dear Friends: The Post-Finasteride Syndrome Foundation is saddened to announce the passing of Daniel M. Stewart. The 37-year-old native of Troy, Michigan, and Centertown, Kentucky, died Saturday, April 12, 2014 at his home in Denton, Texas. Daniel, who suffered from post-finasteride syndrome, had recently taken part in a clinical-research study on the […]
Number of Nations Logging onto PFSFoundation.org Rose 29% in 2013
SOMERSET, N.J., Jan. 6, 2014 – The number of nations that logged onto the Post-Finasteride Syndrome Foundation website rose 29 percent in 2013, according to Google Analytics. In all, users in 120 countries outside the United States—or 61 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed […]
Reminder: Report PFS Symptoms to FDA MedWatch
SOMERSET, N.J., Oct. 29, 2013 – The Post-Finasteride Syndrome Foundation is reminding PFS patients to report all persistent side effects to the FDA MedWatch program. MedWatch is the U.S. Food and Drug Administration’s system for detecting safety-hazard signals for pharmaceutical products and medical devices. If a signal is detected, the FDA can issue safety alerts, […]